ZADH2 Antibody

Basic Research Questions

Proper storage is crucial for maintaining antibody functionality. For ZADH2 antibodies:

• Store at -20°C for long-term stability

• Antibodies are typically stable for one year after shipment when stored properly

• Avoid repeated freeze-thaw cycles to prevent protein degradation

• Most ZADH2 antibodies are supplied in stabilized buffers containing glycerol (typically 50%) and sometimes sodium azide (0.02%)

• For antibodies in PBS with glycerol (pH 7.3), aliquoting is generally unnecessary for -20°C storage

• Upon receipt, antibodies shipped with ice packs should be immediately stored at the recommended temperature

These storage recommendations ensure maintained antibody performance and extended shelf-life for research applications.

What is known about ZADH2 protein structure and localization?

ZADH2 is characterized by:

• A 377 amino acid sequence with a calculated molecular weight of 40 kDa

• Observed molecular weight of 40 kDa on SDS-PAGE, suggesting minimal post-translational modifications

• Membership in the zinc-containing alcohol dehydrogenase family, implying metal binding properties

• Primary subcellular localization in peroxisomes

• UniProt ID: Q8N4Q0

• GenBank Accession Number: BC078661

• NCBI Gene ID: 284273

The peroxisomal localization suggests potential involvement in metabolic processes, particularly those related to detoxification or redox regulation, which are common functions for zinc-binding dehydrogenases.

Advanced Research Questions

Ensuring antibody specificity requires a multi-faceted validation approach:

• Positive and negative tissue controls:

  • Use validated tissues (mouse brain for WB; human pancreas, liver, or gastric cancer for IHC)

  • Include tissues known to lack ZADH2 expression as negative controls

• Molecular weight verification:

  • Confirm band detection at expected 40 kDa in Western blot

  • Evaluate for absence of non-specific bands

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be abolished or significantly reduced in presence of competing peptide

• Knockdown/knockout validation:

  • Use siRNA-mediated knockdown or CRISPR/Cas9 knockout of ZADH2

  • Compare antibody signal between wild-type and knockdown/knockout samples

• Cross-reactivity assessment:

  • Test reactivity across species (human, mouse, rat)

  • Evaluate potential cross-reactivity with other zinc-containing alcohol dehydrogenase family members

These validation approaches should be combined for comprehensive antibody characterization and documented thoroughly in research publications.

How can researchers troubleshoot inconsistent Western blot results with ZADH2 antibodies?

When encountering variable Western blot results with ZADH2 antibodies:

• Sample preparation optimization:

  • Ensure complete protein denaturation (heating at 95°C for 5 minutes in loading buffer)

  • Use protease inhibitors during extraction to prevent ZADH2 degradation

  • Consider specialized extraction methods for peroxisomal proteins

• Blocking optimization:

  • Test different blocking agents (5% non-fat milk vs. 5% BSA)

  • Optimize blocking time (1-2 hours at room temperature or overnight at 4°C)

• Antibody incubation parameters:

  • Adjust antibody dilution within recommended range (1:500-1:1000)

  • Test both room temperature (1-2 hours) and 4°C (overnight) incubation conditions

  • Consider adding 0.05% Tween-20 to reduce background

• Detection system modifications:

  • Compare chemiluminescent vs. fluorescent detection methods

  • For low abundance, use high-sensitivity substrates or signal enhancement systems

• Buffer composition adjustment:

  • Test PBST vs. TBST as washing buffer

  • Adjust salt concentration to reduce non-specific binding

For positive control, mouse brain tissue is recommended as a reliable source for ZADH2 detection in Western blot applications .

What considerations are important when designing multiplex experiments with ZADH2 antibodies?

Designing effective multiplex experiments requires careful planning:

• Antibody compatibility assessment:

  • Ensure all primary antibodies originate from different host species

  • For rabbit polyclonal ZADH2 antibodies , pair with mouse, rat, or goat-derived antibodies against other targets

• Fluorophore selection:

  • Choose fluorophores with minimal spectral overlap

  • Consider signal strength differences between targets (assign stronger fluorophores to less abundant proteins)

• Sequential immunostaining approach:

  • For multiple rabbit antibodies, consider tyramide signal amplification with sequential antibody stripping

  • Validate each antibody individually before multiplexing

• Cross-reactivity controls:

  • Perform single staining controls alongside multiplex experiment

  • Include secondary-only controls to assess non-specific binding

• Image acquisition optimization:

  • Collect individual channels separately to enable post-acquisition correction

  • Use spectral unmixing for closely overlapping fluorophores

For peroxisomal co-localization studies with ZADH2, consider pairing with antibodies against established peroxisomal markers such as catalase or PEX proteins.

How does ZADH2 expression correlate with pathological conditions in current research?

While comprehensive studies on ZADH2 in pathological contexts remain limited, current evidence suggests:

• Cancer tissue expression:

  • ZADH2 antibodies have been validated in human liver cancer, gastric cancer, and pancreatic cancer tissues

  • This suggests potential differential expression in these malignancies

• Chromosome 18-associated disorders:

  • ZADH2 gene is located on chromosome 18, which houses genes associated with multiple disorders

  • These include Trisomy 18, Niemann-Pick disease, hereditary hemorrhagic telangiectasia, erythropoietic protoporphyria, and follicular lymphomas

  • Research potential exists for investigating ZADH2 involvement in these conditions

• Metabolic pathway involvement:

  • As a zinc-binding alcohol dehydrogenase family member localized to peroxisomes

  • May participate in metabolic processes relevant to peroxisomal disorders

• Experimental approach recommendations:

  • Tissue microarray analysis of ZADH2 expression across disease states

  • Correlation of expression levels with clinical outcomes

  • Functional studies using knockdown/overexpression in disease models

Researchers investigating pathological correlations should include appropriate normal tissue controls and quantitative assessment methods when using ZADH2 antibodies for comparative studies.